IL-6RA

OCREVUS data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS)Largest pregnancy safety data across anti-CD20 medicines for OCREVUS in multiple sclerosis (MS) Nine-year safety data for OCREVUS reinforces its favourable benefit-risk profileNew research demonstrates impact of misdiagnosis and delay of starting treatment in NMOSD Basel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 26-28 October 2022. These data include 35 abstracts, highlighting disease activity and progression results in early-stage RRMS, pregnancy outcomes from more than 2,000 women with MS and long-term safety data for OCREVUS, as well as global NMOSD data exploring impact of delayed treatment, clinical characterization of disease severity and stability, and accurate identification of people living with NMOSD through healthcare claims-based algorithms. Finally, the design of a Phase III study evaluating the efficacy and safety of satralizumab in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD), a rare, chronic and debilitating autoimmune disease primarily affecting the optic nerve, brain and spinal cord, will be presented. “Our aim is to enable people living with MS and NMOSD to maintain life to the fullest. With over 250,000 people treated with OCREVUS, we continue to see significant reductions in MS disease progression balanced with favourable safety,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We are also focused on remaining unmet needs – such as earlier diagnosis and treatment – which is critical to ensure patients are receiving the most appropriate treatment.” Multiple sclerosis (MS)Roche will present 29 MS abstracts, including data from a two-year interim analysis of treatment-naive, early-stage patients with RRMS from the open label Phase IIIb ENSEMBLE study that will show the positive impact on disease activity and progression when newly diagnosed patients are treated with OCREVUS, and outcomes from the largest cumulative pregnancy dataset for an anti-CD20 MS medicine in more than 2,000 women treated with OCREVUS. Long-term data from all OCREVUS clinical trials in relapsing MS (RMS) and primary progressive MS (PPMS) over nine years will reinforce the consistently favourable benefit-risk profile of OCREVUS. Neuromyelitis optica spectrum disorder (NMOSD)Roche will present five NMOSD abstracts, including the development and testing of a healthcare claims-based algorithm to identify people living with NMOSD. Misdiagnosis of NMOSD is common and associated with a delay in initiating maintenance therapy. This was highlighted in a study looking to develop a clearer understanding of patient characteristics, relapse severity and other drivers of treatment choice. The development of validated consensus statements on AQP4-IgG seropositive NMOSD management will also be presented with a focus on treatment recommendations including satralizumab; these statements aim to optimise patient outcomes through informed treatment decision making. The characterisation of disease severity and stability in NMOSD will also be presented, with the aim of integrating these in worldwide NMOSD clinical practice. Roche will also present the study design from a Phase III study that will evaluate the efficacy and safety of satralizumab in MOGAD. Follow Roche on Twitter via @Roche and keep up to date with ECTRIMS 2022 news and updates by using the hashtag #ECTRIMS2022. Medicine Abstract title Presentation number (Type) Presentation date Time e-Posters available from 26 October at 8:00 CESTPoster presentations scheduled for 26 October at 16:30-18:30 CEST unless indicated differentlyOCREVUS for MS Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis 0038 (Oral) 26 October14:49-14:56 CEST Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis Showed Low Disease Activity After 2-Year Ocrelizumab Therapy, With No New Safety Signals; The Phase IIIb ENSEMBLE Study P285 (Poster) 27 October13:20-13:25 CEST Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis P326 (Poster) An Interim Analysis of Efficacy and Safety Data in Black and Hispanic Patients With Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial P686 (Poster) Demographics and Baseline Disease Characteristics of Patients With Relapsing Multiple Sclerosis From Kenya Participating in the CHIMES Trial EP1049 (e-Poster) The Patient Perspective on Family Planning Needs and Priorities in Multiple Sclerosis: a Combined Quantitative and Qualitative Research Study P077 (Poster) Blood Neurofilament Light Levels Predict Non-Relapsing Progression Following Anti-CD20 Therapy in Relapsing and Primary Progressive Multiple Sclerosis: Findings From the Ocrelizumab Randomised, Double-Blind Phase 3 Clinical Trials P256 (Poster) Identification of Novel CSF Measures of Disease Activity and Chronic Progressive Biology in MS: Results of the Ocrelizumab Biomarker Outcome Evaluation Study (OBOE): A Randomised, Open-Label Clinical Trial P449 (Poster) 27 October13:34-13:40 CESTReal-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- vs. Second-Line Treatment With Ocrelizumab EP1127 (e-Poster) Trends in the Use of Disease-Modifying Therapies in Pre-Pregnant Women With Multiple Sclerosis in the United States: a Claims Database Analysis P479 (Poster) 27 October17:00-19:00 CEST COVID-19 Vaccination Patterns and Outcomes Among Persons With Multiple Sclerosis in the FlywheelMS Cohort EP1100 (e-Poster) Ocrelizumab in Patients With Early-Stage RRMS – Results From the Phase IIIb ENSEMBLE Trial and the Matched Real-World NTD MS Registry Cohort P771 (Poster) 27 October17:00-19:00 CESTSafety of Shorter Ocrelizumab Infusion Confirmed Over Multiple Administrations: Results of the ENSEMBLE PLUS Substudy P739 (Poster) 27 October17:00-19:00 CEST Efficacy and Safety of Ocrelizumab is Maintained in Patients with RRMS with Suboptimal Response to Prior Disease-Modifying Therapies: 4-Year NEDA Data from CASTING-LIBERTO P289 (Poster) Employment and Cognitive Improvements in Ocrelizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis: 96-Week CASTING Study Data P776 (Poster) 27 October17:00-19:00 CESTCognitive Improvements in Ocrelizumab-Treated Patients with Relapsing-Remitting Multiple Sclerosis: 96-Week CASTING Study Data P377 (Poster) Long-Term Efficacy and Safety of Ocrelizumab in Treatment-Naive Patients With Early Relapsing Multiple Sclerosis: 7-year Data From the OPERA Open-Label Extension Trials P723 (Poster) 27 October13:30-13:35Eight-Year Analyses of Repeated Confirmed Disability Progressions in the OPERA and ORATORIO Studies and Their Open-Label Extensions P050 (Poster) Ocrelizumab Dose Selection for Treatment of Relapsing-Remitting Multiple Sclerosis in Children and Adolescents: Preliminary Pharmacokinetic, Safety and Efficacy Results From the OPERETTA 1 Study P444 (Poster) 27 October17:00-19:00 CEST Infusion-Related Reactions With Ocrelizumab in Relapsing Multiple Sclerosis: Over 9 Years of Data From OPERA OLE P725 (Poster) 27 October 17:00-19:00 CEST SARS-CoV-2 Vaccination and COVID-19 Infections in People With Multiple Sclerosis Treated With Ocrelizumab in the Prospective, Multicenter, Noninterventional MuSicalE and CONFIDENCE Studies P562 (Poster) 27 October 17:00-19:00 CESTSARS-CoV-2 vaccine-induced immune responses and breakthrough infections in people with multiple sclerosis treated with ocrelizumabP553 (Poster) 27 October17:00-19:00 CEST Severe COVID-19 Outcomes Following Vaccination in Persons With Multiple Sclerosis: a Real-World Evidence StudyP747 (Poster) 27 October17:00-19:00 CEST Longitudinal Study of Humoral and Cellular Responses to COVID-19 mRNA Vaccines With and Without 3rd (“Booster”) Dose in MS Patients on Ocrelizumab: 24-Week Results From VIOLA (NCT04843774) EP1052 (e-Poster) Clinical and MRI Outcomes in Pediatric-Onset MS Patients on Ocrelizumab and Fingolimod EP0995 (e-Poster) Floodlight in MS Assessment of Upper Extremity Function and Performance Fatigability in Multiple Sclerosis Using Sensor-Based Features Derived From the Smartphone-Based Pinching Test O144 (Oral) 28 October10:49-10:56 CEST Identification of Distinct Adherence Profiles for Smartphone Sensor-Based Tests (Floodlight) in a Study of People With Progressive Multiple Sclerosis (CONSONANCE) P123 (Poster) Remote Passive Monitoring in People Living With Progressive Multiple Sclerosis During the COVID-19 Pandemic Shows a Measurable Reduction in Daily Activity P522 (Poster) 27 October17:00-19:00 CEST A Prospective Study of the Feasibility of Smartphone-Based Self-Monitoring to Characterise Cognitive and Neurological Impairment in People With Multiple Sclerosis: Floodlight MS MoreActive EP0886 (e-Poster) ENSPRYNG for NMOSD International, evidence-based Delphi consensus on the management of AQP4-IgG seropositive NMOSD, with a focus on treatment recommendations for eculizumab, inebilizumab and satralizumabP008 (Poster) Understanding treatment decisions in neuromyelitis optica spectrum disorder: a global clinical record review with patient interviewsP412 (Poster) 27 October17:00-19:00 CEST Characterisation of disease severity and stability in neuromyelitis optica spectrum disorder: a global clinical record review with patient interviewsP417 (Poster) 27 October17:00-19:00 CEST Development and Validation of a Claims-Based Algorithm to Identify Patients with Neuromyelitis Optica Spectrum Disorder EP0911 (e-Poster) Baseline Characteristics of Initial Patients in the CorEvitas SPHERES Registry for NMOSD P408 (Poster) 27 October 17:00-19:00 CEST satralizumab for MOGADMETEOROID: A Randomised, Double-Blind, Placebo-controlled, Multicentre Phase 3 Study of Satralizumab in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseEP1040(e-Poster) About OCREVUS (ocrelizumab)OCREVUS is the first and only therapy approved for both RMS (including RRMS and active, or relapsing, secondary progressive MS [SPMS], in addition to clinically isolated syndrome [CIS] in the U.S.) and PPMS. OCREVUS is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. This nerve cell damage can lead to disability in people with MS. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved. OCREVUS is administered by intravenous infusion every six months. The initial dose is given as two 300 mg infusions given two weeks apart. Subsequent doses are given as single 600 mg infusions. About ENSPRYNG (satralizumab)ENSPRYNG, which was designed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that targets interleukin-6 (IL-6) receptor activity. ENSPRYNG was designed using novel recycling antibody technology which, compared to conventional technology, allows for longer duration of the antibody and subcutaneous dosing every four weeks. Positive Phase III results for ENSPRYNG, as both monotherapy and in combination with baseline immunosuppressive therapy, demonstrate that IL-6 inhibition is an effective therapeutic approach for neuromyelitis optica spectrum disorder (NMOSD). ENSPRYNG is currently approved for NMOSD in 72 countries with further applications under review with numerous regulators. Roche continues to investigate ENSPRYNG in further indications including generalised myasthenia gravis (gMG), Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) and Autoimmune Encephalitis (AIE). ENSPRYNG was granted Breakthrough Therapy Designation for the treatment of NMOSD by the FDA in December 2018 and designated as an orphan drug for NMOSD in the United States, Europe, Russia and Japan. In addition, it has been designated as an orphan drug for gMG, MOGAD and AIE (NMDAR). About Roche in neuroscienceNeuroscience is a major focus of research and development at Roche. Our goal is to pursue ground-breaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Roche has both approved and investigational medicines across multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, myasthenia gravis, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. Roche Group Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com Hans Trees, PhDPhone: +41 61 687 41 47 Nathalie AltermattPhone: +41 61 687 43 05 Karsten KleinePhone: +41 61 682 28 31 Nina MählitzPhone: +41 79 327 54 74 Dr. Barbara von SchnurbeinPhone: +41 61 687 89 67Sileia Urech Phone: +41 79 935 81 48 Roche Investor Relations Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com Dr. Sabine BorngräberPhone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr. Birgit MasjostPhone: +41 61 68-84814e-mail: birgit.masjost@roche.comDr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com Attachment 19102022_MR_ocrevusECTRIMS_en

New positive data from Evrysdi, a treatment for spinal muscular atrophy (SMA), a progressive neuromuscular disease that can be fatalData from the gene therapy programme for Duchenne muscular dystrophy (DMD), a progressive disease that leads to premature death, reinforce confidence in the most advanced Phase 3 study currently underwayStudy designs of two new trials in generalised myasthenia gravis (gMG), a rare chronic autoimmune disease, and facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder Basel, 05 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its industry-leading neuromuscular portfolio will be presented at the World Muscle Society (WMS) congress, 11th-15th October 2022. These data demonstrate Roche’s commitment to advancing clinical understanding and supporting the development of treatments for people living with neuromuscular disorders. “The continued expansion of our neuromuscular portfolio demonstrates our commitment to developing innovative medicines for a range of neurological disorders,” said Levi Garraway, M.D., Ph. D., Roche’s Chief Medical Officer and Head of Global Product Development. “Through our ongoing research and development and our strong partnerships with patient communities, we continue to address the needs of people with rare neuromuscular conditions.” Spinal muscular atrophy (SMA)SMA is a severe, progressive neuromuscular disease that can be fatal. It is the leading genetic cause of infant mortality, affecting approximately one in 10,000 babies. For the first time, Roche will present new 2-year exploratory efficacy data from the JEWELFISH study in a broad range of patients previously treated with an SMA-targeting therapy, including nusinersen (SpinrazaR) or onasemnogene abeparvovec (ZolgensmaR). Additional data from Evrysdi’s comprehensive clinical development programme will also be presented, including: Preliminary efficacy and safety data from the RAINBOWFISH study, in pre-symptomatic babies from birth to 6 weeks of age (at first dose), which showed that all babies treated with Evrysdi for one-year or more were alive without permanent ventilation, maintained swallowing and feeding abilities, and had not required hospitalisation.Three-year data from the SUNFISH study, further highlighting the long-term efficacy and safety profile of Evrysdi in a broad population of children, teenagers and adults with SMA. Three-year pooled safety and efficacy data from Part 1 and Part 2 of the FIREFISH study which showed that after three years of treatment at the pivotal dose (n=58), 84% of infants were alive and did not require permanent ventilation. Overall, babies maintained or improved their motor skills in terms of developmental milestones and motor function between Month 24 and Month 36. Duchenne muscular dystrophy (DMD)DMD is a rare X-linked, progressive neuromuscular disease caused by mutations in the DMD gene that disrupts the production of functional dystrophin protein, leading to a loss of muscle function and premature death. It is one of the most common fatal genetic disorders, affecting approximately one in every 3,500 to 5,000 male births worldwide. Results from three ongoing clinical trials of gene therapy delandistrogene moxeparvovec in DMD will be presented: Long-term, four-year data from Study 101, an open-label Phase 1/2a study evaluating the safety of delandistrogene moxeparvovec in four ambulatory participants aged between 4-8 years old with DMD. The enduring response and safety observed in the study support the continuation of clinical trials assessing delandistrogene moxeparvovec using single dose gene therapy in patients with DMD.One-year data from ENDEAVOR, an open-label Phase 1b study evaluating the expression and safety of commercially representative delandistrogene moxeparvovec in four cohorts of DMD patients, representing different stages of disease progression. One-year safety and functional data and 12-week expression data from Cohort 1 will be presented. These data reinforce our confidence in the probability of success of EMBARK, our first Phase 3 study using intended commercial process material, which is now fully enrolled. Integrated analyses comparing data from patients treated with delandistrogene moxeparvovec with an external comparator cohort will be presented, including collective safety data from Study 101, Study 102 and ENDEAVOR. Generalised Myasthenia Gravis (gMG)Myasthenia gravis is a rare chronic autoimmune, neuromuscular disease that causes weakness in skeletal muscles. It most commonly affects the muscles that control the eyes and eyelids, facial expressions, chewing, swallowing and speaking as well as limb musculature and muscles of respiration. Roche will present the study design and methodology for LUMINESCE, a Phase 3 randomised, double-blind, placebo-controlled, multicentre study evaluating the efficacy and safety of satralizumab versus placebo on function in daily life in people with gMG. The LUMINESCE study is enrolling a large and broad population of 240 people with gMG, aged 12 years and older, including patients with various disease-causing autoantibodies. Facioscapulohumeral Muscular Dystrophy (FSHD)FSHD is a rare autosomal dominant genetic disorder characterised by progressive weakening of the skeletal muscles in the face, shoulders, arms, trunk and limbs. There is currently no approved therapy for this disease. Roche will present the study design for MANOEUVRE, a multi-center, randomised, placebo-controlled, double-blind, Phase 2 study, that will investigate the effect of GYM329 (RO7204239), an investigational anti-myostatin antibody, in patients with FSHD. The full range of data from Roche’s clinical development programme in neuromuscular disease being presented at WMS 2022 include: Medicine Abstract Title Presentation Number (type), Presentation Date, Time Evrysdi™ (risdiplam) for spinal muscular atrophy RAINBOWFISH: Preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic SMA FP.24 Wednesday 12th October 16.30-16.45 Ballroom FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam in Type 1 SMA P.109 Wednesday 12th October 16.00-17.30 Poster area - Ballroom B1-B2 JEWELFISH: 24-month safety and pharmacodynamic data in non-treatment-naïve patients with SMA P.110 Wednesday 12th October 16.00-17.30 Poster area - Ballroom B1-B2 SUNFISH Parts 1 and 2: 3-year efficacy and safety of risdiplam in Types 2 and 3 SMA P.114 Wednesday 12th October 16.00-17.30 Poster area - Ballroom B1-B2 Real-world experience after one year treating SMA children with risdiplam P.51 Wednesday 12th October 14.30-16.00 Poster area - Ballroom B1-B2 Safety update: Risdiplam clinical trial development program P.113 Wednesday 12th October 16.00-17.30 Poster area - Ballroom B1-B2 The importance of bulbar and respiratory symptoms in spinal muscular atrophy: Results from interviews with patients, caregivers, and healthcare providers P.40 Wednesday 12th October 16.00 - 17.30 Poster area - Ballroom B1 - B2 Delandistrogene moxeparvovec for Duchenne muscular dystrophy Integrated analyses of data from clinical trials of delandistrogene moxeparvovec (SRP-9001) in DMD P.128 Friday 14th October 14.30-16.00 Poster area - Ballroom B1-B2 One-year data from ENDEAVOR, a Phase 1b trial of delandistrogene moxeparvovec (SRP-9001) in boys with DMD P.129 Friday 14th October 14.30-16.00 Poster area - Ballroom B1-B2 Phase 1/2a trial of delandistrogene moxeparvovec (SRP-9001) in patients with DMD: 4-year update P.134a Friday 14th October 14.30-16.00 Poster area - Ballroom B1-B2 A Phase 2 clinical trial evaluating the safety and efficacy of delandistrogene moxeparvovec (SRP-9001) in patients with DMD LSVP.36 Friday 14th October Virtual platform and E-posters Satralizumab for generalised myasthenia gravis LUMINESCE: Phase 3 study of satralizumab, a therapeutic recycling antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis P.92 Wednesday 12th October 16.00-17.30 Poster area - Ballroom B1-B2 GYM329 (RO7204239) for facioscapulohumeral muscular dystrophy MANOEUVRE study design: A study of GYM329 (RO7204239) in patients with FSHD P.141 Friday 14th October 14.30-16.00 Poster area - Ballroom B1-B2 Full session details and data presentations listing for the WMS 2022 Hybrid Congress can be found at the meeting website: www.worldmusclesociety.org Follow Roche on Twitter via @Roche and keep up to date with WMS 2022 Congress news and updates by using the hashtag #RocheAtWMS2022, #WMS and #neuromuscular About Evrysdi (risdiplam)Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to survival motor neuron (SMN) protein deficiency. Evrysdi is administered daily at home in liquid form by mouth or by feeding tube. Evrysdi is designed to treat SMA by increasing and sustaining the production of the SMN protein in the central nervous system (CNS) and peripheral tissues. SMN protein is found throughout the body and is critical for maintaining healthy motor neurons and movement. Evrysdi was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by the U.S Food and Drug Administration in 2017. In 2021, Evrysdi was awarded Drug Discovery of the Year by the British Pharmacological Society as well as the Society for Medicines Research award for Drug Discovery. Evrysdi is currently approved in 91 countries and the dossier is under review in a further 18 countries. To date, more than 7,000 adults, children and babies have been treated with Evrysdi worldwide. About delandistrogene moxeparvovecDelandistrogene moxeparvovec (SRP-9001; rAAVrh74.MHCK7.micro-dystrophin) is an investigational gene therapy aimed to deliver the micro-dystrophin-encoding transgene directly to the skeletal and cardiac muscle for the targeted production of the SRP-9001-dystrophin protein to enable a durable clinical response. In December 2019, Roche partnered with Sarepta to combine Roche’s global reach and drug development and regulatory expertise to accelerate access to delandistrogene moxeparvovec for patients About ENSPRYNG® (satralizumab)ENSPRYNG, which was designed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that targets interleukin-6 (IL-6) receptor activity. ENSPRYNG was designed using novel recycling antibody technology which, compared to conventional technology, allows for longer duration of the antibody and subcutaneous dosing every four weeks. Positive Phase III results for ENSPRYNG, as both monotherapy and in combination with baseline immunosuppressive therapy, demonstrate that IL-6 inhibition is an effective therapeutic approach for neuromyelitis optica spectrum disorder ( NMOSD). ENSPRYNG is currently approved for NMOSD in 72 countries with further applications under review with numerous regulators. Roche continues to investigate ENSPRYNG in further indications including generalised myasthenia gravis (gMG), Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) and Autoimmune Encephalitis (AIE). ENSPRYNG has been designated as an orphan drug for gMG, MOGAD, AIE (NMDAR) and NMOSD in the United States. ENSPRYNG has also been designated as an orphan drug for NMOSD in Europe, Russia and Japan. In addition, it was granted Breakthrough Therapy Designation for the treatment of NMOSD by the FDA in December 2018. About GYM329 (RO7204239)GYM329 is an investigational anti-myostatin antibody that is designed to increase muscle growth by binding to inhibiting myostatin, a natural negative regulator of muscle growth. By binding to the protein, GYM329 was created with the aim of blocking the function of myostatin, therefore helping muscles to grow in size and strength. About Roche in NeuroscienceNeuroscience is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Roche has both approved and investigational medicines across multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, myasthenia gravis, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. Spinraza is a registered trademark of Biogen MA Inc. Zolgensma is a registered trademark of Novartis AG. Roche Group Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com Hans Trees, PhDPhone: +41 61 687 41 47 Nathalie AltermattPhone: +41 61 687 43 05 Karsten KleinePhone: +41 61 682 28 31 Nina MählitzPhone: +41 79 327 54 74 Dr. Barbara von SchnurbeinPhone: +41 61 687 89 67 Sileia Urech Phone: +41 79 935 81 48 Roche Investor Relations Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com Dr. Sabine BorngräberPhone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr. Birgit MasjostPhone: +41 61 68-84814e-mail: birgit.masjost@roche.com Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com Attachment 05102022_MR_WMS2022_en

PrecisionLife's unique combinatorial analytics approach to understanding the drivers of disease biology in patient subgroups has revealed hundreds of new commercial opportunities to reposition patented drugs and drug candidates into novel indications, with significant near-term additional revenue potential for pharmaceutical companies Careful indication extension or repositioning of drugs coupled with patient stratification biomarkers to identify responders can provide a faster, cheaper and derisked route to the approval of new therapies, with major benefits to patients with unmet medical needs The peer-reviewed study highlighted 477 potential repositioning opportunities in over 35 secondary disease indications across the development and marketed drug pipelines of 177 companies OXFORD, England, June 13, 2022 /PRNewswire/ -- PrecisionLife Limited, a global techbio company generating the deepest insights into disease biology to create novel precision medicine opportunities in chronic diseases, has published data showing the significant opportunities for biopharma companies to rapidly develop new treatments for patients with unmet medical needs through precision repositioning. "The successful global effort to find effective interventions for the most severe COVID-19 patients demonstrated the value of reusing current drugs in new indications" said Dr Steve Gardner, CEO of PrecisionLife and co-author on a new paper published in a Cell Patterns special edition focusing on AI Drug Discovery. "Generic drugs such as dexamethasone were rapidly tested, and some proved effective in managing severely ill patients during the pandemic." Now a new peer-reviewed publication, entitled 'Systematic Indication Extension for Drugs Using Patient Stratification Insights generated by Combinatorial Analytics'1 has revealed that pharmaceutical companies are sitting on a gold mine in their patented drug portfolios, with the potential to bring new treatments to market faster and cheaper across more than 35 chronic diseases. The data shows 477 potential repositioning opportunities within the pipelines and marketed assets of 177 biopharma companies, based on deep analysis of shared mechanisms and patient stratification biomarkers in the secondary indications. Such therapies could address the unmet medical needs of millions of patients with multi-billion dollar additional revenue potential. Indication extension or repositioning of drugs, is the identification of additional therapeutic indications for patented medicines, an opportunity that can create additional returns on the capital invested in a drug's original R&D. Such opportunities arise because the biological mechanisms driving patients' disease are often common between multiple diseases. High-resolution stratification of patients allows developers to find drugs whose targets are involved in causing multiple diseases within mechanistically defined patient subgroups. PrecisionLife's proprietary combinatorial analytics approach to patient stratification underpins its INDx indication extension platform. With its unique insights, PrecisionLife has been able to systematically match the patented drug assets of hundreds of pharmaceutical companies to clinically relevant patient subgroups who will benefit from treatments targeting the mechanisms and biological drivers of their disease in secondary indications. Further checks for dosage, route of administration, toxicity, and freedom to operate are used to validate all opportunities. Repositioning opportunities cited in the publication include a specific mineralocorticoid receptor antagonist for patients with renal complications arising from type 2 diabetes and an IL6R antagonist useful in a subgroup of ALS (Amyotrophic Lateral Sclerosis) patients. "Patients need better therapeutic options, and the pace and productivity of the pharma industry needs to improve. Combinatorial analytics and high-resolution patient stratification have the potential to enhance the rate of innovation across the drug discovery industry. This can reduce drug development risk and increase revenue at the same time as offering patients the hope of rapid access to new, more personalized therapeutic options for a wide range of underserved diseases and patient subgroups" concludes Dr Gardner. About PrecisionLife PrecisionLife is changing the way the world looks at predicting, preventing, and treating chronic diseases. Its unique proven and scalable combinatorial analysis approach generates more insights from patient data than any other methods, revealing the drivers of disease biology and stratifying patients at an unprecedented level of resolution. PrecisionLife operates a hybrid business model – developing a drug discovery pipeline in house and out-licensing novel targets and indication extension assets for co-development with biopharma partners. Understanding disease biology better uniquely enables PrecisionLife to power patient-focused precision drug discovery and predict and prevent chronic diseases to transform outcomes in healthcare, delivering a new age of better, more personalized therapy options – to improve health, for everyone. PrecisionLife is a private company headquartered near Oxford, UK and operations in Aalborg and Copenhagen, Denmark, Warsaw, Poland and Cambridge, MA, USA. For more information see Follow us on LinkedIn (precisionlifeAI) and Twitter (@precisionlifeAI) 1 Das S, Taylor K, Beaulah S, Gardner S. Systematic indication extension for drugs using patient stratification insights generated by combinatorial analytics. Cell Patterns. 2022 June; 3(6). SOURCE PrecisionLife